Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
Do you include trastuzumab in the treatment regimen of patients with advanced stage HER2+ endometrial cancer that is NOT serous or carcinosarcoma?
Answer from: at Community Practice
Yes, I do, and other anti-HER2 agents as well, especially for those with recurrrent disease.
Sign in or Register to read more
19545
Related Questions
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
How do you classify extensive LVSI in endometrial cancer?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?